Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

65 results about "Ivermectinum" patented technology

Anti-parasitic ivermectin transdermal solution used for livestock and preparation method thereof

The invention relates to an anti-parasitic ivermectin transdermal solution used for livestock and a preparation method thereof. The anti-parasitic ivermectin transdermal solution comprises the following components respectively according to parts by volume: 5 to 15 parts of ethyl acetate, 20 to 30 parts of dimethyl sulfoxide, 2 to 6 parts of azone, 1 to 3 parts of isopropanol and 50 to 70 parts of propanediol; and the content of ivermectin is 0.3g to 1g in a solution of 100ml, and the finished product is prepared by the processes of dissolving, mixing, filtering and filling. The azone related in the prescription of the invention is a novel skin penetration enhancer, can increase the transdermal absorption of the skin to various medicines of different types, effectively avoids the pass effect of hepar, avoids peak and valley phenomena in the absorption process of the medicine, reduces the toxic or side effect caused by the correlative dosage in the medicine, prolongs the effective effect time, changes the administration area, effectively regulates the administration dosage and reduces differences among individuals. The invention has the characteristic of simple, convenient and fast use, and is more suitable for the anti-parasitic prevention and treatment of a pasturing area compared with other preparation forms.
Owner:TIANJIN BIJIA PHARMA CO LTD

Compositions comprising C-13 alkoxyether macrolide compounds and phenylpyrazole compounds

ActiveUS20070293446A1High instantaneous effectivenessLong effectivenessBiocideSugar derivativesMedicinal chemistryParasite infestation
Provided is a novel ivermectin derivative and compositions for the treatment or prophylaxis of parasite infestations in mammals or birds which comprise: (A) a pharmaceutically effective amount of a 1-N-phenylpyrazole compound; (B) a pharmaceutically effective amount of an ivermectin derivative of formula (II) wherein: R14 represents —(CH2)sO—Z  wherein,  s is 1 or 2; Y represents —CH(OR15)—, —C(═O)— or —C(═NOR15); R15 represents hydrogen, alkyl or phenyl; and R16 represents —CH3 or —CH2CH3; Z is alkyl, alkenyl, alkynyl, acyl, alkylalkoxy, aryl, alkanoyloxy, alkoxycarbonyl, alkenoyl, alkynoyl, or aroyl.
Owner:MERIAL INC

Compound ivermectin albendazole transdermal agent for livestock and application method thereof

The invention belongs to the technical field of preparation of medicament for livestock, and particularly relates to a compound ivermectin albendazole transdermal agent for livestock and an application method thereof. The transdermal agent is a mixture of two or three components below at any proportion: ivermectin, albendazole, solubilizer tween-80, a laurocapram transdermal accelerant, a 95% ethanol diluent, an N-methyl-pyrrolidone and propylene glycol. When the transdermal agent is used for treating parasitic diseases of animals such as pigs and sheep, the transdermal agent is flow-coated from the head part to the tail root part along a dorsal line after hairs at the back part are uniformly pushed aside towards two sides, and good treatment effect can be obtained after the transdermal agent is used continuously for three days. The preparation method of the compound ivermectin albendazole transdermal agent for livestock is simple; in comparison with other dosage form in the prior art, the medicine use way is simpler and more convenient, and more dosage is saved; as no liver first-pass effect exists, influence from gastric emptying rate and the like is avoided, the irritability reaction degree of the animals is low, the treatment effect is better, the treatment way is convenient and fast, and the operation is easy.
Owner:河南亚卫动物药业有限公司

Mdr1 variants and methods for their use

This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation.
Owner:WASHINGTON STATE UNIVERSITY

Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds

Pharmaceutical / dermatological emulsions containing at least one avermectin compound, notably ivermectin, include at least one fatty phase and at least one aqueous phase, the at least one avermectin compound being solubilized in the fatty phase, which emulsions are useful for the treatment of a variety of dermatological conditions / afflictions, in particular rosacea.
Owner:GALDERMA HLDG SA

Pharmaceutical composition for treating chicken coccidiosis and preparation method thereof

The invention discloses a pharmaceutical composition for treating chicken coccidiosis. The pharmaceutical composition is prepared from the following components by weight: 0.25 to 2.5 parts of ivermectin, 2.5 to 25 parts of antifeverile dichroa root extract, 15 to 25 parts of astragalus extract, 15 to 25 parts of dark plum extract, 10 to 15 parts of hairyvein agrimony extract and 500 parts of purified attapulgite. The invention also provides a preparation method for the pharmaceutical composition. The invention has the following advantages: the pharmaceutical composition provided by the invention has an anticoccidial index of more than 195 and is composed of both traditional Chinese medicines and western medicines; and an adjuvant material in an oral preparation is attapulgite, so slow release effect is exerted, residues are hardly left, so the pharmaceutical composition has obvious advantages. According to results of in-vitro anticoccidial sporlating test and artificial treatment effect test of chicks infected with coccidia, the traditional Chinese medicine composition provided by the invention has anticoccidial effect; so the composition facilitates further confirmation of the application scope of a compound medicine, provides related enterprises with a novel approach to develop high-quality products, broadens novel application fields of medicine resources, lays a good foundation for research and development of a novel anticoccidial medicine and is of obvious significance.
Owner:河北美荷药业有限公司

Albendazole and ivermectin premix as well as preparation method and application thereof

The invention discloses an albendazole and ivermectin premix as well as a preparation method and application thereof, and relates to the technical field of veterinary drugs. The albendazole and ivermectin premixing agent is prepared from the following components in percentage by mass: 5.5 to 6.5 percent of albendazole, 0.2 to 0.3 percent of ivermectin, 4 to 6 percent of activated carbon, 55 to 65 percent of polyethylene glycol and 25 to 35 percent of glyceryl monostearate. The preparation method comprises the following steps: heating, melting, emulsifying and stirring the components to form a medicine suspension, and carrying out spray drying and condensation on the medicine suspension to form spherical particles. According to the albendazole and ivermectin premixing agent provided by the invention, the dosage of albendazole and ivermectin is controlled, specific auxiliary materials are selected, albendazole and ivermectin are dispersed in molten liquid of the auxiliary materials, and spherical fine particles are formed through spray drying and condensation, so that the albendazole and ivermectin premixing agent is prepared. The albendazole and ivermectin premixing agent prepared by the invention can be uniformly mixed and is good in dispersity.
Owner:江西博莱兽药科技协同创新有限公司

Application of composition to preparation of veterinary anti-parasitic drug, transdermal solution of veterinary anti-parasitic drug and preparation method of transdermal solution

InactiveCN111514157ASolve the problem of small range of deworming by single applicationReduce labor costsOrganic active ingredientsPharmaceutical delivery mechanismAntiparasiticGlycerol
The invention belongs to the technical field of an anti-parasitic drug, and particularly relates to an application of a composition containing ivermectin and levamisole hydrochloride to preparation ofa veterinary anti-parasitic drug, a transdermal solution of the veterinary anti-parasitic drug and a preparation method of the transdermal solution. The transdermal solution comprises components in parts by volume as follows: 20-50 parts of isopropanol, 10-40 parts of glycerol, 10-30 parts of absolute ethyl alcohol, 5-20 parts of dimethyl sulfoxide and 2-6 parts of azone; the content of ivermectin is 0.3-1 g per 100 mL of solution, and the content of levamisole hydrochloride is 5-15 g per 100 mL of solution. According to the invention, ivermectin and levamisole hydrochloride are combined, a synergistic effect is realized by simultaneous use of ivermectin and levamisole hydrochloride, and an anti-parasitic spectrum is improved; and meanwhile, with adoption of a transdermal absorption dosage form, toxic and side effects caused by correlation of the drug and the dosage are reduced, and a simultaneous internal and external anti-parasitic effect of the preparation is realized.
Owner:吉林吉力生物技术研究有限公司 +2

Veterinary albendazole/ivermectin dry suspension

The invention relates to a veterinary anthelmintic, and particularly relates to a veterinary albendazole/ivermectin dry suspension with using convenience and significant drug effects. The dry suspension is prepared by steps of stirring 0.1-0.2 part of ivermectin and 2-4 parts of sodium carboxymethylcellulose and mixing, adding 2-4 parts of a flavoring agent after the powder is mixed uniformly, and mixing uniformly again; stirring 5-15 parts of albendazole and 10-20 parts of sodium chloride and mixing, adding 5-10 parts of sodium citrate after the powder is mixed uniformly, and mixing uniformly again; adding the former into the latter through an equivalent increment method, and stirring uniformly; adding the balance of other auxiliary material, and further uniformly stirring and mixing; and subpackaging to obtain the finished product. The other auxiliary material is soluble starch or microcrystalline cellulose. The dry suspension can be proportionally added in an automatic drinker directly for use, thus facilitating all-round dosing in a large-size livestock farm. The dry suspension avoids the toxic and side effect caused by non-uniform feed mixing, and is more convenient to use. The drug effect is remarkably enhanced, and the cost is obviously lowered in comparison with the prior art. The dry suspension has a wide application prospect.
Owner:SICHUAN DERUNTONG BIOTECH

Albendazole ivermectin enteric-coated sustained-release pellet and preparation method thereof

PendingCN113318090AQuality improvementGood disintegration and dissolution in the intestinal tractOrganic active ingredientsPharmaceutical non-active ingredientsSustained release pelletsNematode
The invention discloses an albendazole ivermectin enteric-coated sustained-release pellet. The albendazole ivermectin enteric-coated sustained-release pellet is prepared by taking classical anthelmintic drug combination albendazole ivermectin powder (10% albendazole and 0.2% ivermectin) as an active ingredient and adding proper auxiliary materials, and comprises a pellet core layer and an enteric-coated layer, wherein the weight percentage of the pellet core layer and the enteric-coated layer is as follows: 70-85% of pellet core and 15-30% of enteric-coated layer. The invention further discloses a preparation method and application of the enteric-coated sustained-release pellet. The enteric-coated sustained-release pellet disclosed by the invention is used for expelling and killing in-vivo and in-vitro parasites such as pig nematodes, trematodes, tapeworms, mites and lice. The albendazole and the ivermectin both have certain toxicity, the bioavailability of the common albendazole ivermectin powder orally taken by pigs is only 40-50%, and toxic and side effects are often caused if an effective dose is expected in clinical use; the enteric-coated sustained-release pellet disclosed by the invention can release a large amount of drugs only in an intestinal environment with a pH value of 6.8 or above, thus reducing the damages of an acidic stomach environment to the drugs; amd the drugs are stably and slowly released in the intestinal tract, the maintenance time of an effective blood concentration is prolonged, the bioavailability is 80% or above, the clinical dosage can be reduced by 30% or above, the safety is greatly improved, and the application prospect is wide.
Owner:WUHAN XINLIANDA BIOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products